Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
Moderna said people without insurance will be able to get its COVID vaccine at no cost after the U.S. government bows out. But patients will have to use the company's cumbersome assistance program.
-
An insulin maker is cutting its prices. Eli Lilly, one of the three makers of insulin products in the United States, is also making other moves toward affordability for people with diabetes.
-
The U.S. Food and Drug Administration late last year got more leverage over pharmaceutical companies that received accelerated approvals for their drugs. How will the agency use its new powers?
-
A federal judge is set to rule in a case challenging the FDA's approval of an abortion pill decades ago. Siding with the anti-abortion group may have ripple effects on drug approvals as we know them.
-
A shortage of both generic and brand-name Adderall began in October. That's left many ADHD patients without their needed medication.
-
The FDA announced the supply troubles in the fall. Four months later, the medication remains hard to get and could stay that way until the spring -
When a pharmaceutical drug has been on the market a while, it's supposed to go generic and the price is supposed to go down. For blockbuster arthritis drug Humira, that hasn't happened — until now.
-
At-home rapid tests have become a staple of COVID-19 precautions, but some experts worry that people are relying too much on these tests and that's creating a false sense of security. -
Changes by the FDA mean patients won't have to schedule in-person exams to get a prescription. That opens the door for more pharmacies to provide the medication. But not everyone will have access. -
The abortion pill Mifepristone, which has only been available in person in certain clinics, could become accessible at local drugstores and retail pharmacy chains, as well as via telehealth.
